{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:37:18Z","timestamp":1784684238240,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Acute Myeloid Leukemia (AML) is a malignancy of myeloid precursor cells that arise from genomic alterations in the expression of key growth regulatory genes causing cells to assume an undifferentiated state and continue to proliferate. Recent efforts have focused on developing therapies that target specific protein products of aberrantly expressed genes. However, many of the identified proteins are difficult to target and thought to be \u201cundrugable\u201d because of structural challenges, protein overexpression, or mutations that confer resistance to therapy. A novel technology that circumvents some of these issues is the use of small molecules that stabilize secondary DNA structures present in the promoters of many potential oncogenes and modulate their transcription.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This study characterizes the in vitro activity of the G-quadruplex-stabilizing small molecule GQC-05 in AML cells. The effect of GQC-05 on three AML cell lines was analyzed using viability and apoptosis assays. GQC-05 has been shown to down-regulate MYC through G-quadruplex stabilization in Burkitt\u2019s lymphoma cell lines. MYC expression was evaluated through qPCR and immunoblotting in the three AML cell lines following the treatment of GQC-05. In order to identify other therapeutic agents that potentiate the activity of GQC-05, combination drug screening was performed. The drug combinations were validated using in vitro cytotoxicity assays and compared to other commonly used chemotherapeutic agents.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>GQC-05 treatment of KG-1a, CMK and TF-1 cells decreased cell viability and resulted in increased DNA damage and apoptosis. Additionally, treatment of KG-1a, CMK and TF-1 with GQC-05 resulted in decreased expression of MYC mRNA and protein, with a more pronounced effect in KG-1a cells. Combination drug screening identified the Bcl-2\/Bcl-X<jats:sub>L<\/jats:sub> inhibitor Navitoclax as a compound that potentiated GQC-05 activity. Co-treatment with GQC-05 and Navitoclax showed a synergistic decrease in cell viability of AML cells as determined by Chou-Talalay analysis, and induced more DNA damage, apoptosis, and rapid cytotoxicity. The cytotoxicity induced by GQC-05 and Navitoclax was more potent than that of Navitoclax combined with either cytarabine or doxorubicin.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>These results suggest that the G-quadruplex stabilizing small molecule GQC-05 induces down regulated MYC expression and DNA damage in AML cells. Treatment with both GQC-05 with a Bcl-2\/Bcl-X<jats:sub>L<\/jats:sub> inhibitor Navitoclax results in increased cytotoxic activity, which is more pronounced than Navitoclax or GQC-05 alone, and more significant than Navitoclax in combination with cytarabine and doxorubicin that are currently being used clinically.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-019-6464-9","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T18:02:42Z","timestamp":1577469762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8538-301X","authenticated-orcid":false,"given":"Justin J.","family":"Montoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan A.","family":"Turnidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Wai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurvi R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Gokhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence H.","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Arceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Wetmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Azorsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,27]]},"reference":[{"issue":"12","key":"6464_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"key":"6464_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.gde.2016.03.011","volume":"36","author":"S Li","year":"2016","unstructured":"Li S, Mason CE, Melnick A. Genetic and epigenetic heterogeneity in acute myeloid leukemia. Curr Opin Genet Dev. 2016;36:100\u20136.","journal-title":"Curr Opin Genet Dev"},{"issue":"1","key":"6464_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24(1):103\u201312.","journal-title":"Nat Med"},{"issue":"8","key":"6464_CR4","doi-asserted-by":"publisher","first-page":"10041","DOI":"10.1007\/s13277-016-5067-1","volume":"37","author":"M Kavianpour","year":"2016","unstructured":"Kavianpour M, Ahmadzadeh A, Shahrabi S, Saki N. Significance of oncogenes and tumor suppressor genes in AML prognosis. Tumour Biol. 2016;37(8):10041\u201352.","journal-title":"Tumour Biol"},{"issue":"8","key":"6464_CR5","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-15-1015","volume":"76","author":"JE Farrar","year":"2016","unstructured":"Farrar JE, Schuback HL, Ries RE, Wai D, Hampton OA, Trevino LR, Alonzo TA, Guidry Auvil JM, Davidsen TM, Gesuwan P, et al. Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse. Cancer Res. 2016;76(8):2197\u2013205.","journal-title":"Cancer Res"},{"issue":"1","key":"6464_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","volume":"2016","author":"CD DiNardo","year":"2016","unstructured":"DiNardo CD, Cortes JE. Mutations in AML: prognostic and therapeutic implications. Hematol Am Soc Hematol Educ Program. 2016;2016(1):348\u201355.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"14","key":"6464_CR7","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1093\/nar\/gkl529","volume":"34","author":"J Eddy","year":"2006","unstructured":"Eddy J, Maizels N. Gene function correlates with potential for G4 DNA formation in the human genome. Nucleic Acids Res. 2006;34(14):3887\u201396.","journal-title":"Nucleic Acids Res"},{"issue":"18","key":"6464_CR8","doi-asserted-by":"publisher","first-page":"8627","DOI":"10.1093\/nar\/gkv862","volume":"43","author":"D Rhodes","year":"2015","unstructured":"Rhodes D, Lipps HJ. G-quadruplexes and their regulatory roles in biology. Nucleic Acids Res. 2015;43(18):8627\u201337.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"6464_CR9","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/nrg3296","volume":"13","author":"ML Bochman","year":"2012","unstructured":"Bochman ML, Paeschke K, Zakian VA. DNA secondary structures: stability and function of G-quadruplex structures. Nat Rev Genet. 2012;13(11):770\u201380.","journal-title":"Nat Rev Genet"},{"issue":"18","key":"6464_CR10","doi-asserted-by":"publisher","first-page":"11593","DOI":"10.1073\/pnas.182256799","volume":"99","author":"A Siddiqui-Jain","year":"2002","unstructured":"Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci U S A. 2002;99(18):11593\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"47","key":"6464_CR11","doi-asserted-by":"publisher","first-page":"41018","DOI":"10.1074\/jbc.M111.274720","volume":"286","author":"RV Brown","year":"2011","unstructured":"Brown RV, Danford FL, Gokhale V, Hurley LH, Brooks TA. Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex. J Biol Chem. 2011;286(47):41018\u201327.","journal-title":"J Biol Chem"},{"issue":"4","key":"6464_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.semcancer.2006.07.015","volume":"16","author":"M Vita","year":"2006","unstructured":"Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. 2006;16(4):318\u201330.","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"6464_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1177\/1947601910377494","volume":"1","author":"EV Prochownik","year":"2010","unstructured":"Prochownik EV, Vogt PK. Therapeutic targeting of Myc. Genes Cancer. 2010;1(6):650\u20139.","journal-title":"Genes Cancer"},{"issue":"3","key":"6464_CR14","first-page":"559","volume":"1","author":"N Miura","year":"1998","unstructured":"Miura N, Sato T, Fuse A, Okimoto Y, Kinugawa N, Horie H, Ota S, Kakuda H, Yokoe H, Miya T, et al. Establishment of a new human megakaryoblastic cell line, CMY, with chromosome 17p abnormalities. Int J Mol Med. 1998;1(3):559\u201363.","journal-title":"Int J Mol Med"},{"issue":"1","key":"6464_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood.V74.1.42.42","volume":"74","author":"N Komatsu","year":"1989","unstructured":"Komatsu N, Suda T, Moroi M, Tokuyama N, Sakata Y, Okada M, Nishida T, Hirai Y, Sato T, Fuse A, et al. Growth and differentiation of a human megakaryoblastic cell line, CMK. Blood. 1989;74(1):42\u20138.","journal-title":"Blood"},{"issue":"3\u20134","key":"6464_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3109\/10428190009148861","volume":"36","author":"T Sato","year":"2000","unstructured":"Sato T, Sekine H, Kakuda H, Miura N, Sunohara M, Fuse A. HIV infection of megakaryocytic cell lines. Leuk Lymphoma. 2000;36(3\u20134):397\u2013404.","journal-title":"Leuk Lymphoma"},{"key":"6464_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27\u201355.","journal-title":"Adv Enzym Regul"},{"issue":"6","key":"6464_CR18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101\u20138.","journal-title":"Nat Protoc"},{"issue":"6","key":"6464_CR19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/1947601910377493","volume":"1","author":"TA Brooks","year":"2010","unstructured":"Brooks TA, Hurley LH. Targeting MYC expression through G-Quadruplexes. Genes Cancer. 2010;1(6):641\u20139.","journal-title":"Genes Cancer"},{"issue":"17","key":"6464_CR20","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1111\/j.1742-4658.2010.07759.x","volume":"277","author":"TA Brooks","year":"2010","unstructured":"Brooks TA, Kendrick S, Hurley L. Making sense of G-quadruplex and i-motif functions in oncogene promoters. FEBS J. 2010;277(17):3459\u201369.","journal-title":"FEBS J"},{"issue":"9","key":"6464_CR21","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1021\/jm900055s","volume":"52","author":"D Sun","year":"2009","unstructured":"Sun D, Hurley LH. The importance of negative superhelicity in inducing the formation of G-quadruplex and i-motif structures in the c-Myc promoter: implications for drug targeting and control of gene expression. J Med Chem. 2009;52(9):2863\u201374.","journal-title":"J Med Chem"},{"issue":"5","key":"6464_CR22","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532\u201342.","journal-title":"Blood"},{"issue":"7","key":"6464_CR23","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1128\/MCB.24.7.2890-2904.2004","volume":"24","author":"C Muller-Tidow","year":"2004","unstructured":"Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, Sargin B, Kohler G, Stelljes M, Puccetti E, et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol. 2004;24(7):2890\u2013904.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"6464_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00280-015-2766-z","volume":"76","author":"S Brondfield","year":"2015","unstructured":"Brondfield S, Umesh S, Corella A, Zuber J, Rappaport AR, Gaillard C, Lowe SW, Goga A, Kogan SC. Direct and indirect targeting of MYC to treat acute myeloid leukemia. Cancer Chemother Pharmacol. 2015;76(1):35\u201346.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"6464_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1182\/blood.V62.4.709.709","volume":"62","author":"HP Koeffler","year":"1983","unstructured":"Koeffler HP. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood. 1983;62(4):709\u201321.","journal-title":"Blood"},{"issue":"2","key":"6464_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/jcp.1041400219","volume":"140","author":"T Kitamura","year":"1989","unstructured":"Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, Piao YF, Miyazono K, Urabe A, Takaku F. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol. 1989;140(2):323\u201334.","journal-title":"J Cell Physiol"},{"issue":"6","key":"6464_CR27","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1158\/1535-7163.MCT-17-1209","volume":"17","author":"A Local","year":"2018","unstructured":"Local A, Zhang H, Benbatoul KD, Folger P, Sheng X, Tsai CY, Howell SB, Rice WG. APTO-253 stabilizes G-quadruplex DNA, inhibits MYC expression, and induces DNA damage in acute myeloid leukemia cells. Mol Cancer Ther. 2018;17(6):1177\u201386.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"6464_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s12185-012-1196-5","volume":"96","author":"S Cruet-Hennequart","year":"2012","unstructured":"Cruet-Hennequart S, Prendergast AM, Shaw G, Barry FP, Carty MP. Doxorubicin induces the DNA damage response in cultured human mesenchymal stem cells. Int J Hematol. 2012;96(5):649\u201356.","journal-title":"Int J Hematol"},{"key":"6464_CR29","doi-asserted-by":"publisher","first-page":"41950","DOI":"10.1038\/srep41950","volume":"7","author":"J Ma","year":"2017","unstructured":"Ma J, Li X, Su Y, Zhao J, Luedtke DA, Epshteyn V, Edwards H, Wang G, Wang Z, Chu R, et al. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells. Sci Rep. 2017;7:41950.","journal-title":"Sci Rep"},{"issue":"7327","key":"6464_CR30","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067\u201373.","journal-title":"Nature"},{"issue":"9","key":"6464_CR31","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421\u20138.","journal-title":"Cancer Res"},{"issue":"5","key":"6464_CR32","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/leu.2013.377","volume":"28","author":"NM Anderson","year":"2014","unstructured":"Anderson NM, Harrold I, Mansour MR, Sanda T, McKeown M, Nagykary N, Bradner JE, Lan Zhang G, Look AT, Feng H. BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines. Leukemia. 2014;28(5):1145\u20138.","journal-title":"Leukemia"},{"issue":"12","key":"6464_CR33","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1158\/1535-7163.MCT-11-0415","volume":"10","author":"J Chen","year":"2011","unstructured":"Chen J, Jin S, Abraham V, Huang X, Liu B, Mitten MJ, Nimmer P, Lin X, Smith M, Shen Y, et al. The Bcl-2\/Bcl-X(L)\/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011;10(12):2340\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"15","key":"6464_CR34","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1021\/acs.jmedchem.7b00298","volume":"60","author":"S Kendrick","year":"2017","unstructured":"Kendrick S, Muranyi A, Gokhale V, Hurley LH, Rimsza LM. Simultaneous drug targeting of the promoter MYC G-Quadruplex and BCL2 i-motif in diffuse large B-cell lymphoma delays tumor growth. J Med Chem. 2017;60(15):6587\u201397.","journal-title":"J Med Chem"},{"issue":"2","key":"6464_CR35","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/nar\/gkx1122","volume":"46","author":"C Weldon","year":"2018","unstructured":"Weldon C, Dacanay JG, Gokhale V, Boddupally PVL, Behm-Ansmant I, Burley GA, Branlant C, Hurley LH, Dominguez C, Eperon IC. Specific G-quadruplex ligands modulate the alternative splicing of Bcl-X. Nucleic Acids Res. 2018;46(2):886\u201396.","journal-title":"Nucleic Acids Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6464-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6464-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6464-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T00:14:38Z","timestamp":1608941678000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6464-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6464"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6464-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"2 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Laurence Hurley and Vijay Gokhale have a financial interest in Reglagene, a G-quadruplex- targeting company. The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1251"}}